Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05525416
Other study ID # Pro00096808
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 28, 2022
Est. completion date February 5, 2023

Study information

Verified date March 2023
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate sex differences in blood pressure control associated with exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high altitude.


Description:

About 200 million people worldwide live at high altitudes and millions of others travel to high altitude every year for work or pleasure. At high altitude participants are exposed to a lower than normal level of oxygen, also known as hypoxia. This causes stress to the human body, which will adapt in order to maintain adequate oxygen delivery to its tissues. One of these adaptations is an increase in activity of participants' sympathetic nervous system ("fight or flight" response). Sympathetic nerve activity affects the size of participants' blood vessels, which in turn will affect blood pressure. Men and women regulate their blood pressure in different ways; for example, women tend to have lower blood pressure and sympathetic nerve activity than men. Women also appear to have less constriction of their blood vessels in response to stress. This may be in part because estrogen causes blood vessels to dilate. It may also be due to differences in the receptors which are activated by the sympathetic nervous system. These receptors are called alpha and beta receptors and respond to sympathetic nerve activity in opposite directions. Women represent 50% of the population living at and travelling to high altitude, therefore, it is important to understand the differences in how men and women respond to low oxygen. The main purpose of this study is to examine the differences between men and women in the sympathetic nervous system control of blood vessels during exposure to low oxygen. To study this question, the investigators will test how blood vessels respond to stressors in both men and women. Participants will be recruited at the Canadian sites, and the investigators will test them while they breathe low oxygen for a short amount of time at low altitude. The investigators will also perform assessments on the same participants during a two week stay at high altitude at White Mountain, CA, which is at an altitude of 3,800m. These data will have implications in the basic understanding of differences between male and female physiology. Specifically, to males and females living or travelling to high altitude.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date February 5, 2023
Est. primary completion date February 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Between ages of 18-50 - No medical history of cardiovascular, respiratory, nervous system, or metabolic disease - Females must be pre-menopausal Exclusion Criteria: - Any known cardiovascular, respiratory, nervous system, or metabolic disease (however, participants with controlled arterial hypertension will not be excluded) - Having travelled above 2,000m within 1 month of testing at low and high altitude - Females who are pregnant, confirmed by a pregnancy test - Females who are post-menopausal - Participants that are classified as obese (body mass index > 30kg·m²) - Participants who are current daily smokers - Those with a known allergy to sulfites - Participants taking monoamine oxidase (MAO) inhibitors or tricyclic antidepressants or other medications that have contraindications with the study drugs - Participants who are still within the washout period from participating in other studies involving drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sodium Nitroprusside
A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
Phenylephrine Hydrochloride
A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
Phenylephrine Hydrochloride
Investigators will give three incremental doses via brachial artery catheter to observe a1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
Norepinephrine
Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
Other:
Isometric Handgrip and Post-Exercise Circulatory Occlusion
Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
Rhythmic Handgrip
Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
Cold Pressor Test
Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
Drug:
Propranolol Hydrochloride
Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
Phentolamine Mesylate
Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta
Canada University of British Columbia - Okanagan Kelowna British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, Joyner MJ. Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension. 2009 Mar;53(3):571-6. doi: 10.1161/HYPERTENSIONAHA.108.126391. Epub 2009 Jan 26. — View Citation

Mazzeo RS, Child A, Butterfield GE, Mawson JT, Zamudio S, Moore LG. Catecholamine response during 12 days of high-altitude exposure (4, 300 m) in women. J Appl Physiol (1985). 1998 Apr;84(4):1151-7. doi: 10.1152/jappl.1998.84.4.1151. — View Citation

Purdy GM, James MA, Rees JL, Ondrus P, Keess JL, Day TA, Steinback CD. Spleen reactivity during incremental ascent to altitude. J Appl Physiol (1985). 2019 Jan 1;126(1):152-159. doi: 10.1152/japplphysiol.00753.2018. Epub 2018 Nov 21. — View Citation

Usselman CW, Gimon TI, Nielson CA, Luchyshyn TA, Coverdale NS, Van Uum SH, Shoemaker JK. Menstrual cycle and sex effects on sympathetic responses to acute chemoreflex stress. Am J Physiol Heart Circ Physiol. 2015 Mar 15;308(6):H664-71. doi: 10.1152/ajpheart.00345.2014. Epub 2014 Dec 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in systolic, diastolic, and mean arterial blood pressure modified oxford 3 minutes
Primary Change in arterial blood flow phenylephrine and norepinephrine sensitivity 1 hour 30 minutes
Primary Change in vascular conductance exercise and metaboreflex reactivity 20 minutes
Primary Cold pressor test sympathetic reactivity 3 minutes
Primary Propranolol changes in vascular conductance 2 hours
Primary Phentolamine changes in vascular conductance 1 hour
See also
  Status Clinical Trial Phase
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT05997732 - Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences Phase 4
Recruiting NCT06117007 - Effects of Betalains on Cardiovascular Health and Quality of Life N/A
Active, not recruiting NCT03659864 - The Role of Eicosanoids in the Cardiovascular Actions of Inhaled Nanoparticles N/A
Completed NCT03459027 - Nitrate Supplementation and Muscle Blood Flow N/A
Recruiting NCT04255160 - Impact of Estradiol on Endothelial Function in Peri-Menopausal Women Phase 4
Recruiting NCT05522075 - Reducing Blood Pressure in Mid-life Adult Binge Drinkers N/A
Completed NCT00184886 - The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans N/A
Completed NCT02095873 - Healthy Aging Through Functional Food Phase 1/Phase 2
Completed NCT02292342 - An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men Phase 0
Completed NCT00901745 - Interaction of Apelin and Angiotensin in the Human Forearm Circulation N/A
Not yet recruiting NCT06290713 - Vasodilator and Exercise Study for DMD (VASO-REx) Phase 2
Completed NCT02265107 - Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft N/A
Recruiting NCT05219799 - Sex Disparities in Hypoxic Vasodilation and Impact of Obesity Early Phase 1
Completed NCT03622060 - Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion Phase 3
Completed NCT01618071 - Vascular Effects of Triglyceride-rich Lipoproteins N/A
Completed NCT03190304 - The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure Phase 4
Completed NCT04928183 - The Impact of Carbon Monoxide and Altitude on Vascular Function N/A
Suspended NCT04001647 - Targeting ER Stress in Vascular Dysfunction Early Phase 1
Completed NCT03605095 - Evidence of Spreading Vasodilation in Human Gingiva N/A